Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain
ConditionHerpes Zoster
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Tiantan Hospital
About this trial
To assess the 1-month effects and safety of esketamine - PRF -standardized drug treatment against PRF -standardized drug treatment acute/subacute zoster-associated pain (ZAP) patients.
Eligibility criteria
Qualifiers
Ages more than 18 years;
Patients with onset of herpes zoster (HZ) rash less than 90 days;
HZ affected the spinal nerves (cervical/thoracic/lumbar nerve);
Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)；
Disqualifiers
Obstructive sleep apnoea syndrome;
Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.
A history of systemic immune diseases, organ transplantation, or cancers;
A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;
Trial design
Treatments tested in this trial
- esketamine group
- PRF group
Treatment groups
184 Participants
are divided into 2 treatment groupsLocations
1Beijing Tiantan Hospital100070, BeijingBeijing Municipality, China
Sponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
Beijing Xiaotangshan Hospital
Collaborator
The First Hospital of Fangshan District,Beijing
Collaborator
Beijing Ditan Hospital
Collaborator
Hengshui People's Hospital
Collaborator
Source ClinicalTrials.gov